Product Description
human placenta-derived cells for Peripheral Arterial Disease and Diabetic Foot Ulcer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01859117)
Mechanisms of Action: Immunomodulator
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intramuscular
FDA Designation: Orphan Drug - Muscular Dystrophies|Muscular Dystrophy, Facioscapulohumeral *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Celularity
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Diabetic Foot|Peripheral Arterial Disease|Peripheral Vascular Diseases|Peripheral Nervous System Diseases|Diabetic Nephropathy
Phase 1: Peripheral Arterial Disease|Diabetic Foot|Peripheral Vascular Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CCT-PDA-002-DFU-002 | P2 |
Terminated |
Peripheral Arterial Disease|Diabetic Foot|Peripheral Vascular Diseases |
2018-02-28 |
24% |
| CCT-PDA-002-DFU-003 | P2 |
Withdrawn |
Diabetic Foot|Peripheral Arterial Disease|Peripheral Vascular Diseases |
2017-09-01 |
|
| CCT-PDA-002-DPN-001 | P2 |
Completed |
Peripheral Nervous System Diseases|Diabetic Nephropathy |
2017-03-07 |
24% |
| CCT-PDA-002-DFU-001 | P1 |
Completed |
Peripheral Arterial Disease|Peripheral Vascular Diseases|Diabetic Foot |
2016-10-01 |
22% |